GLP-1 medications have been shown to support heart health by improving lipid profiles and reducing visceral fat
Individual genetic sensitivity to each pathway varies significantly
It helps detoxify heavy metals and environmental toxins
This protective effect was primarily driven by a 30% reduction in liver decompensation events, comprising ascites, hepatic encephalopathy, variceal bleeding, and hepatorenal syndrome (IRR: 0.70, 95%CI: 0.52-0.94, P = 0.020), based on six studies comprising 877,488 participants
GLP-1 drugs include semaglutide, liraglutide and dulaglutide, now marketed as Ozempic, Wegovy, Saxenda, Victoza and Trulicity
It analyzes the latest scientific findings, potential mechanisms of action, and how these drugs compare to existing treatment options